Fulvestrant has been also approved in combination with the PI3K inhibitor alpelisib for PIK3CA-mutant HR+, HER2− locally advanced or metastatic BC after progression from first-line treatment with a single agent hormonal therapy [14,15]. The gene discussed is PIK3CA; the disease is breast cancer.